Application of active component of sanguisorba officinalis to preparation of antitumor medicines

An anti-tumor, multi-purpose technology, applied in the field of medicine, can solve unseen problems

Inactive Publication Date: 2018-10-30
SOUTHWEST MEDICAL UNIVERISTY
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, there is no literature report on the active ingredient in Burnet Ulmus that has dual effects of vascular inhibition and cytotoxicity, and no active ingredient based on this dual effect can simultaneously inhibit the expression of VEGF, PI3K, mTOR mRNA and protein in HUVEC cells, thereby Inhibit the growth of tumor blood vessels, and promote the expression of Bax, Bcl-2 and Caspase-3 mRNA and protein in tumor cells, and play a dual mechanism of cytotoxicity, so as to play a safe and significant anticancer effect on common cancer tumor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of active component of sanguisorba officinalis to preparation of antitumor medicines
  • Application of active component of sanguisorba officinalis to preparation of antitumor medicines
  • Application of active component of sanguisorba officinalis to preparation of antitumor medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1 The effect of 3,3',4'-trimethoxy inverse gallic acid on inhibiting the proliferation of human umbilical vein endothelial cells HUVEC cells

[0053] With 5% FBS (fetal bovine serum, Fetal bovine serum, Gibco, specification: 500mL / bottle, batch number: 42Q9462K), 1% penicillin-streptomycin mixture (Beyotime, specification: 100mL / bottle, batch number: C0222), 1 % Endothelial cell growth factor ECGS ECM complete medium (Sciencell, specification: 500mL / bottle, batch number: 1001), at 37 ° C, 5% CO 2 HUVEC cells were cultured in an incubator, and the medium was changed every other day. When the cell confluence was about 90%, the 1:2 subculture was carried out.

[0054] Take HUVEC cells in good growth state and digest them with trypsin, take 10 μL of cell suspension and count on the counting plate, adjust the cell density to 3×10 4 cells / mL, 3000 cells / well were inoculated in a 96-well plate, 100 μL per well. After the cells adhered to the wall, the medium was remo...

Embodiment 2

[0057] Example 2 The effect of 3,3',4'-trimethoxy inverse gallic acid on inhibiting the migration of human umbilical vein endothelial cells HUVEC cells

[0058] The effect of TMEA on the migration ability of HUVEC cells was investigated by scratch test. The Marker pen, ruler, 200 μL sterile pipette tip and other experimental equipment used in the experiment were placed in the ultra-clean bench for 30 minutes of ultraviolet irradiation in advance. The specific experimental steps are as follows, repeated three times:

[0059] Before cell inoculation, use a Maker pen to evenly draw 3 horizontal lines on the back of the 6-well plate, and wait for the ink to dry. After digesting HUVEC cells in good growth state with trypsin digestion solution, count on the counting plate and adjust the cell density to 1×10 6 Cells / mL were inoculated in a 6-well plate, 1 mL per well, the cells were evenly spread on the bottom of the 6-well plate, and cultured in an incubator for 24 hours.

[0060]...

Embodiment 3

[0067] Example 3 The effect of 3,3',4'-trimethoxy retrogallic acid on inhibiting tubule formation of human umbilical vein endothelial cells HUVEC cells in vitro

[0068] The Martrigel matrigel was liquefied overnight in a refrigerator at 4°C in advance, and all pipette tips used in the experiment had to be liquefied in a refrigerator at 4°C overnight to avoid uneven glue surfaces. During the experiment, Matrigel was always kept on ice to avoid its solidification affecting its use.

[0069] Spread 50 μL of liquefied Martrigel matrigel in each well of a 96-well plate, shake slightly on ice to evenly distribute it on the bottom of the 96-well plate, and then transfer it to a 37°C incubator for 30 minutes to solidify. After Matrigel was fully solidified, 2×10 5 cells / mL of the drug-containing cell suspension, after incubation in the incubator, observe the tubule formation under a 40× microscope. A blank group, a sorafenib group (10 μmol / mL) and five different concentrations (40,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, particularly discloses application of an active component 3,3',4'-trimethoxy ellagic acid of sanguisorba officinalis to preparation of antitumor medicines, and discloses the 3,3',4'-trimethoxy ellagic acid. The 3,3',4'-trimethoxy ellagic acid inhibits angiogenesis through down-regulation of VEGF expression and inhibition of phosphorylation of PI3K/AKT/mTOR, induces tumor cell apoptosis through activation of a Bax/Bcl-2/Caspase-3 pathway, has a dual-effect antitumor effect of inhibiting tumor angiogenesis and cytotoxicity, and has a good therapeutic effect during application to preparation of anticancer medicinal preparations.

Description

technical field [0001] The invention belongs to the field of medicine, and specifically relates to the use of 3,3',4'-trimethoxyinverse gallic acid, an active ingredient of Burnet burnet, in the preparation of an angiogenesis-inhibiting and cytotoxic double-effect anti-tumor drug. Background technique [0002] Cancer, namely malignant tumor, is a kind of disease with high fatality rate, which seriously threatens people's life and health. According to the "Global Cancer Report 2014" published by WHO, since 2012, the morbidity and mortality of cancer patients in the world have gradually increased every year, and a considerable number of new cancer cases have been found in China [1]. Among the four major malignant tumors (liver, lung, stomach and esophageal cancer), China ranks first in the world in new cases and deaths. According to statistics, in 2012, the number of cancer patients in China accounted for about 1 / 5 of the global number of patients, about 3.065 million; cancer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P35/00
CPCA61K31/366A61P35/00
Inventor 吴建明秦大莲柏冲飞杨靖孙悦珊
Owner SOUTHWEST MEDICAL UNIVERISTY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap